Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
AstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.
Original title: “AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow”
The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.
Original title: “New Taiho, Cullian data heats up lung cancer drug battle”
Jideytro offers option for previously treated patients
Original title: “GSK wins US approval for ROS1 lung cancer therapy”
The clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British drugmaker into oncology.
Original title: “GSK lung cancer drug gets speedy approval following $10.6B deal”
The results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for front-line lung cancer.
Original title: “Merck ADC, in China study, shows potential to replace chemo in lung cancer”
GSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among cancer drugmakers.
Original title: “GSK, Hansoh ADC extends survival in lung cancer study”
paraneoplastic neurologic syndrome in advanced lung cancer with mixed adenocarcinoma and squamous features a diagnostic challenge a case report
Original title: “Paraneoplastic neurologic syndrome in advanced lung cancer with mixed adenocarcinoma and squamous features: a diagnostic challenge-a case report.”
Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.
Original title: “Merck, Gilead report mixed outcomes in key lung cancer, HIV studies”
While Merck and Gilead Sciences reported back-to-back late-stage victories for their weekly HIV pill, the partners also discontinued a Phase 3 program for their cancer combo after disappointing lung cancer survival data.
Original title: “Merck, Gilead serve ‘sweet and sour’ spread after HIV win, cancer stumble”
While many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet.
Original title: “Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?”
Pfizer showcased multiple late-breakers at the American Society of Clinical Oncology’s annual conference but its biggest data are expected later this year.
Original title: “ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come”
Practice-changing data in lung cancer, prostate cancer and more were on display over the weekend at the American Society of Clinical Oncology annual meeting in Chicago. Plus, early readouts on assets that could reshape the cancer landscape.
Original title: “ASCO: A battle of bispecifics, Eli Lilly’s big win and more”
“King Keytruda's reign continues,” analysts at BMO Capital Markets declared after Chinese data for Summit Therapeutics’ ivonescimab were revealed at the American Society for Clinical Oncology in Chicago.
Original title: “ASCO: Summit reached with China lung data but new climb begins to prove global benefit”
Interim overall survival data on a TROP2 ADC from Merck and Chinese partner Kelun-Biotech provide support for the pharma’s big bet on its potential to help navigate Keytruda’s impending loss of exclusivity.
Original title: “ASCO: Kelun-Merck ADC shines with differentiated overall survival in first-line lung cancer”
Analysts, investors and partner Summit Therapeutics had all been keenly awaiting the overall survival update, after previous data from Akeso’s HARMONi-6 trial left them wanting.
Original title: “ASCO: Akeso’s VEGF/PD-1 boosts lung cancer survival, relieving pressure on US partner Summit”
Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important barometer for a class of cancer immunotherapies known as "PD-1/VEGF inhibitors."
Original title: “Akeso, Summit drug extends survival in closely watched lung cancer trial”
Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly improved” as compared to placebo—the second positive readout for the asset this week.
Original title: “Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival”
hepatoid adenocarcinoma of the lung clinicopathologic and molecular analysis of 17 cases
Original title: “Hepatoid adenocarcinoma of the lung: clinicopathologic and molecular analysis of 17 cases.”
David Ross: Continuing Advocacy for Rare Diseases Two Decades After Losing a Loved One / cancer, David Ross, IPF, Karen Yada Ross, Lung cancer, Natera, Karen continues to advocate for rare diseases such as PH-ILD with a sense of dedication, humility, and compassion. As part of the Pulmovant team, she aspires to make a meaningful difference for these courageous patients.”
Original title: “David Ross: Continuing Advocacy for Rare Diseases Two Decades After Losing a Loved One - OncoDaily”
primary hepatoid adenocarcinoma of the lung with signet ring cell differentiation and widespread osseous metastases a case report
Original title: “Primary Hepatoid Adenocarcinoma of the Lung With Signet Ring Cell Differentiation and Widespread Osseous Metastases: A Case Report.”